BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 24899058)

  • 1. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
    Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular smooth muscle cells contribute to APOL1-induced podocyte injury in HIV milieu.
    Lan X; Wen H; Saleem MA; Mikulak J; Malhotra A; Skorecki K; Singhal PC
    Exp Mol Pathol; 2015 Jun; 98(3):491-501. PubMed ID: 25796344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
    Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
    Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?
    Olabisi O; Al-Romaih K; Henderson J; Tomar R; Drummond I; MacRae C; Pollak M
    Clin Nephrol; 2016 Supplement 1; 86 (2016)(13):114-118. PubMed ID: 27509583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
    Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
    Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein domains of APOL1 and its risk variants.
    Lan X; Wen H; Lederman R; Malhotra A; Mikulak J; Popik W; Skorecki K; Singhal PC
    Exp Mol Pathol; 2015 Aug; 99(1):139-44. PubMed ID: 26091559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
    Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
    Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy.
    Bruggeman LA; Wu Z; Luo L; Madhavan S; Drawz PE; Thomas DB; Barisoni L; O'Toole JF; Sedor JR
    PLoS One; 2019; 14(10):e0224408. PubMed ID: 31661509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
    Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of APOL1 polymorphism and IL-1β priming in the entry and persistence of HIV-1 in human podocytes.
    Mikulak J; Oriolo F; Portale F; Tentorio P; Lan X; Saleem MA; Skorecki K; Singhal PC; Mavilio D
    Retrovirology; 2016 Sep; 13(1):63. PubMed ID: 27599995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tripartite complex of suPAR, APOL1 risk variants and α
    Hayek SS; Koh KH; Grams ME; Wei C; Ko YA; Li J; Samelko B; Lee H; Dande RR; Lee HW; Hahm E; Peev V; Tracy M; Tardi NJ; Gupta V; Altintas MM; Garborcauskas G; Stojanovic N; Winkler CA; Lipkowitz MS; Tin A; Inker LA; Levey AS; Zeier M; Freedman BI; Kopp JB; Skorecki K; Coresh J; Quyyumi AA; Sever S; Reiser J
    Nat Med; 2017 Aug; 23(8):945-953. PubMed ID: 28650456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing rare and common APOL1 coding variants to determine kidney disease risk.
    Limou S; Nelson GW; Lecordier L; An P; O'hUigin CS; David VA; Binns-Roemer EA; Guiblet WM; Oleksyk TK; Pays E; Kopp JB; Winkler CA
    Kidney Int; 2015 Oct; 88(4):754-63. PubMed ID: 25993319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.
    Anyaegbu EI; Shaw AS; Hruska KA; Jain S
    Pediatr Nephrol; 2015 Jun; 30(6):983-9. PubMed ID: 25530085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOL1 variants associate with increased risk of CKD among African Americans.
    Foster MC; Coresh J; Fornage M; Astor BC; Grams M; Franceschini N; Boerwinkle E; Parekh RS; Kao WH
    J Am Soc Nephrol; 2013 Sep; 24(9):1484-91. PubMed ID: 23766536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
    Ekulu PM; Adebayo OC; Decuypere JP; Bellucci L; Elmonem MA; Nkoy AB; Mekahli D; Bussolati B; van den Heuvel LP; Arcolino FO; Levtchenko EN
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOL1 localization in normal kidney and nondiabetic kidney disease.
    Madhavan SM; O'Toole JF; Konieczkowski M; Ganesan S; Bruggeman LA; Sedor JR
    J Am Soc Nephrol; 2011 Nov; 22(11):2119-28. PubMed ID: 21997392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.
    Bruggeman LA; Wu Z; Luo L; Madhavan SM; Konieczkowski M; Drawz PE; Thomas DB; Barisoni L; Sedor JR; O'Toole JF
    J Am Soc Nephrol; 2016 Dec; 27(12):3600-3610. PubMed ID: 27026370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.
    Hawkins GA; Friedman DJ; Lu L; McWilliams DR; Chou JW; Sajuthi S; Divers J; Parekh RS; Li M; Genovese G; Pollack MR; Hicks PJ; Bowden DW; Ma L; Freedman BI; Langefeld CD
    Am J Nephrol; 2015; 42(2):99-106. PubMed ID: 26343748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.
    Gutiérrez OM; Judd SE; Irvin MR; Zhi D; Limdi N; Palmer ND; Rich SS; Sale MM; Freedman BI
    Nephrol Dial Transplant; 2016 Apr; 31(4):602-8. PubMed ID: 26152403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
    Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
    Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.